Navigation Links
Binex and MaxCyte Collaborate on Cancer Immunotherapy Research
Date:11/30/2007

BUSAN, South Korea and GAITHERSBURG, Md., Nov. 30 /PRNewswire/ -- Binex (KOSDAQ: 053030) and MaxCyte, Inc. announced today the signing of a Sponsored Research Agreement to evaluate MaxCyte's GMP-compliant cell loading technology for use in closed-system manufacturing of Binex's cell-based cancer immunotherapies. Upon completion of the research studies, the agreement provides Binex an option to license MaxCyte's technology for clinical and commercial use in Korea. Financial terms were not disclosed.

"Based upon its impressive capabilities, we believe MaxCyte's cell loading technology can be an important component of our closed system," said Baek Chun Lee, Ph.D., Binex's Chairman. "Our immunotherapy product is currently undergoing review by the Korean FDA for colorectal and non-small cell lung cancers and clinical studies are in progress for breast and gastrointestinal cancers. We expect cell immunotherapies to continue to be a core business for Binex. As we advance this therapy, we are developing a closed system manufacturing process which will allow us to improve scalability and reduce cost for making inroads into world markets. We believe MaxCyte's technology can contribute significantly as we expand this product toward new indications."

"We are extremely pleased to be working with Binex to advance their promising cancer vaccine. Our technology has been shown to be uniquely effective, capable of producing cell-based therapeutics that are highly reproducible, with the scalability and efficiency needed for commercial use," said Douglas Doerfler, President and CEO of MaxCyte. "Binex's readiness to partner with MaxCyte validates both the enablement of our cell loading technology platform and their leadership as a life sciences company."

About Binex

Binex Co., Ltd. is a publicly traded specialized pharmaceutical company located in Busan, Korea developing a broad range of pharmaceutical products such as nutrients and vitamin compounds, and intestinal antiseptic concentrated with probiotics screened by Binex. Binex is also developing a strong anti-cancer franchise based around their DC-Vac and ANYCELL cell bank businesses. BINEX went public in 2001 on the Korean Stock Exchange and recorded sales of $30 million in 2007 fiscal year.

For more information, visit http://www.bi-nex.com

About MaxCyte

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary, non-viral, ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to commercializing successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at the Center for Biologics Evaluation and Research (CBER).

For more information, visit http://www.maxcyte.com.


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
2. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
3. Rice, Nanyang Tech collaborate on sustainable nanoelectronics
4. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
5. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
6. Monsanto and Evogene Collaborate on Nitrogen Use Efficiency Research
7. Project on Emerging Nanotechnologies and Consumers Union collaborate on ConsumersTalkNano
8. New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study
9. Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... regulatory compliance requirements for life science products comes to New Orleans, Philadelphia and ... the regulatory agencies in Latin America and discuss local cultural nuances for working ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Cynvenio Biosystems, ... launch of a new neoadjuvant breast cancer monitoring (NEAT) study in partnership with Allentown, ... centers and over 150 patients to be monitored over two years with Cynvenio’s ClearID ...
(Date:4/28/2017)... ... 28, 2017 , ... While things have been quiet for EcoloCap over the ... a new outlook for the future. As a continued effort to bring innovative ... retirement of Mr. Siegel as CEO. With the new adjustments in management, EcoloCap has ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... organization (CRO) has validated a 0.2 ng/mL lower limit (LLOQ) assay for nicotine ... 0.5 ng/mL LLOQ assay, the ultra-low trace nicotine assay meets additional needs of ...
Breaking Biology Technology:
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
Breaking Biology News(10 mins):